Around the globe, the growing class of weight loss drugs called GLP-1 agonists has been a game-changer
Key Players Driving Growth: Novo Nordisk, Sanofi, Eli Lilly and Company., Merck Group, AstraZeneca, Boehringer Ingelheim, Novartis, Johnson & Johnson (Janssen), Pfizer, Roche, Takeda, Bayer, Bristol Myers Squibb, Amgen, SUN PHARMA, Lupin, Cipla, Teva Pharmaceuticals, MannKind Corporation, Biocon
Clinical studies show an average of 15% body weight loss over 68 weeks with semaglutide, and up to 2022% with tirzepatide
Lets connect and explore how this smart ingredient can enhance your portfolio
Belmar operates both 503A state-licensed pharmacies and FDA-registered 503B outsourcing facilities across six locations, licensed in 49 states
Clinical studies show that patients using semaglutide lose significantly more weight than those on diet and exercise alone, with many achieving sustained results over 12 months or longer